Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 billion, representing nearly 20% growth from 2024 at the midpoint and well above analysts’ projections compiled by Visible Alpha. Vertex's fourth-quarter revenue of $2.91 billion was up 16% year-over-year and also exceeded the analyst consensus. Adjusted earnings of $1.04 billion, or $3.98 per share, fell fr ...